A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. The index has shown a price loss of -97.60% this year. Over the last six months, there has been a stronger performance of -83.71%. The price of REVB leaped by -60.44% during the last 30 days period. For the last 5-days stocks have slided -18.18%.
Revelation Biosciences Inc ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $25.26 on 01/29/24, while the lowest value for the same period was recorded at $0.40 on 12/13/24.
52-week price history of REVB Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Revelation Biosciences Inc’s current trading price is -98.57% away from its 52-week high, while its distance from the 52-week low is -10.16%. The stock’s price range during this period has varied between$0.40 and $25.26. The Revelation Biosciences Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.55 million for the day, a figure considerably lower than their average daily volume of 1.0 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Revelation Biosciences Inc (REVB) has experienced a quarterly decline of -59.96% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.63M and boasts a workforce of 9 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.9089, with a change in price of -1.2900. Similarly, Revelation Biosciences Inc recorded 1,628,697 in trading volume during the last 100 days, posting a change of -78.18%.
REVB’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for REVB stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
REVB Stock Stochastic Average
As of today, Revelation Biosciences Inc’s raw stochastic average for the last 50 days stands at 3.09%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 3.45%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 2.78% and 3.38%, respectively.